Abstract
Type 2 diabetes is a chronic metabolic disorder that is becoming a leading cause of morbidity and mortality. The prolonged time-course of human type 2 diabetes makes modelling of the disease difficult and additional animal models and methodologies are needed. The goal of this study was to develop and characterise a new method that allows controlled, targeted and sustained induction of discrete stages of type 2 diabetes in rodents. Using adult, male rats, we employed a three-week high fat-diet regimen and confirmed development of obesity-associated glucose intolerance, a key feature of human type 2 diabetes. Next, we utilised osmotic mini-pumps to infuse streptozotocin (STZ; doses ranging 80â200âmg/kg) over the course of 14-days to decrease insulin-producing capacity thus promoting hyperglycemia. Using this new approach, we demonstrate a dose-dependent effect of STZ on circulating glucose and insulin levels as well as glucose tolerance, while retaining a state of obesity. Importantly, we found that insulin secretion in response to a glucose load was present, but reduced in a dose-dependent manner by increasing STZ. In conclusion, we demonstrate a novel method that enables induction of discrete stages of type 2 diabetes in rodents that closely mirrors the different stages of type 2 diabetes in humans.
Similar content being viewed by others
Introduction
Among the different forms of diabetes, type 2 diabetes accounts for approximately 90% of cases and current estimates indicate that by 2040, approximately 642 million world-wide people will be living with type 2 diabetes1,2. This is likely to be a conservative estimate given that for every case of diagnosed type 2 diabetes, we know there is likely an additional, undiagnosed case1,2. This is most concerning in developing countries where as many as 50% of diabetics are undiagnosed and living with uncontrolled hyperglycemia1,2, the primary risk factor for development of cardiovascular, metabolic and neuronal disorders associated with the disease3,4,5,6. Therefore, development of animal models that accurately replicate the pathogenesis of human type 2 diabetes is of paramount importance and will enable identification of preventative and therapeutic strategies targeting both type 2 diabetes and associated pathologies.
Type 2 diabetes is a complex, chronic disorder and most people with type 2 diabetes progress through an early stage of obesity-associated insulin resistance prior to development of frank hyperglycemia5,6. With continuing insulin resistance, a compensatory increase in insulin production maintains normal circulating glucose concentrations5,6,7. This physiological shift impacts pancreatic beta cells early in disease progression and with time, leads to exhaustion of beta cell insulin production, clinically manifesting as frank type 2 diabetes6. The time-course of pre-clinical and then clinical type 2 diabetes progression can be incredibly long and thus makes modelling discrete stages of type 2 diabetes incredibly difficult.
With the exception of genetic models, which are costly and do not accurately model human type 2 diabetes, the most commonly used animal model of type 2 diabetes is the high fat diet (HFD) fed rodent injected with streptozotocin (STZ)8,9,10,11,12. This model accelerates the time-course of type 2 diabetes by initiating a state of obesity-associated insulin resistance using a period of HFD feeding7,13, followed by an injection of STZ to deplete pancreatic beta cells8,14. A few days after STZ administration, these animals develop severe hyperglycemia in the near absence of insulin production, exhibit marked weight loss and have short life expectancy15. These physiological changes currently confine the HFDâ+âSTZ model to investigation of end-stage type 2 diabetes, which more closely resembles type 1 diabetes16,17. Some studies have utilised multiple low-dose STZ injections and argue that this approach enables better control of the ensuing hyperglycemia based on the notion that smaller, repeated insults impart greater control over the extent of beta cell death18,19. However, while leading to short-term hyperglycemia, long-term studies (â¥four weeks) are confounded by the ability of the remaining beta cells to compensate/regenerate resulting in a reversion toward normoglycemia20,21. This is particularly evident in younger rodents and suggests that the efficacy of injection methods may also be markedly influenced by the age at which STZ is injected20,21. Given these limitations, the aim of the current study was to develop a new animal model that allows targeted and sustained induction of discrete stages of type 2 diabetes where animals remain obese, exhibit mild-moderate hyperglycemia and retain the ability to produce insulin, or those that exhibit frank type 2 diabetes.
Results
STZ is stable over a 14-day period
Due to the slow release of STZ from the mini-pump, we first investigated the stability of STZ in citrate buffer across 14-days (delivery period of the mini-pump) at 37â°C. Over the course of two-weeks, STZ degradation was approximately 20% (Fig. 1A). The ratio of alpha/beta STZ anomers reached equilibrium (43/57%, respectively) within the first two hours of dissolution and remained constant across the two-week period (Fig. 1B).
Rats given a HFD and osmotic mini-pump-infused STZ exhibited increased body weight and adiposity
While water intake was not altered by HFD, food intake was greater in all HFD-fed groups relative to control diet (CD) across the first three weeks (Supplementary Table 1). In all groups, HFD feeding led to increased body weight compared CD-fed rats across the first three weeks and only the two highest doses of STZ (150âmg/kg and 200âmg/kg) led to weight loss at the end of the five-week period (Fig. 2B). Epididymal fat mass (a surrogate marker of adiposity) was approximately 2-fold higher in all HFD-fed animals compared to CD (pâ<â0.05 for all) with the exception of the 150âmg/kg and 200âmg/kg STZ groups (Fig. 2C), where there was no difference. Similarly, all HFD fed rats exhibited 2â3 fold higher circulating non-esterified fatty acid (NEFA) concentrations relative to CD (Fig. 2D; pâ<â0.001 for all).
Osmotic mini-pump-infused STZ dose-dependently increased fasting glucose and decreased fasting insulin concentrations
Non-fasting glucose concentrations were assessed in all animals twice weekly up to day 20 and then daily from days 21â34 (Supplementary Figure 1). Six days post-mini pump implant, non-fasting glucose concentrations were increased, but not statistically different from vehicle at STZ doses ranging from 80â110âmg/kg. Animals that received 120âmg/kg STZ had increased non-fasting glucose by day five and this remained higher than vehicle across the reminder of the intervention (pâ<â0.01). The two highest doses of STZ tested caused a rapid and overt increase in non-fasting glucose concentrations 2â3 days following mini-pump implant. In both cases, glucose concentrations exceeded 20.0âmmol/l within 6â7 daysâ post-implant. The experimental protocols in these two groups were concluded early (days 32 and 28, respectively) due to rapid weight loss (Fig. 2B) and animal health and wellbeing.
All animals were fasted overnight prior to glucose tolerance tests on days 0, 20 and 35. Fasting blood glucose concentrations were not different between groups at baseline or day 20 (Fig. 3A). On day 35, fasting glucose was increased in animals treated with 80âmg/kg STZ (6.7â±â0.1âmmol/l), 90âmg/kg STZ (6.5â±â0.3âmmol/l) and 100âmg/kg STZ (6.4â±â0.3âmmol/l) compared with their respective values on day 0 and day 20 (pâ<â0.05 for all), but did not reach significance versus vehicle (5.7â±â0.3âmmol/l). Relative to vehicle, fasting glucose was increased in animals that received 110âmg/kg STZ (7.2â±â0.2âmmol/l) and 120âmg/kg STZ (9.0â±â1.3âmmol/l). Increasing STZ further to 150âmg/kg and 200âmg/kg resulted in extreme increases in fasting glucose (pâ<â0.001 for both vs vehicle).
Compared with CD-fed animals (41â±â4 pmol/l), fasting insulin concentrations (Fig. 3B) were significantly higher in HFD (95â±â20 pmol/l), vehicle (91â±â14 pmol/l), 80âmg/kg (75â±â7 pmol/l) and 90âmg/kg (70â±â8 pmol/l) STZ groups (pâ<â0.05 for all). In animals that received 100âmg/kg (57â±â11 pmol/l), 110âmg/kg (50â±â8 pmol/l) and 120âmg/kg (43â±â5 pmol/l) doses of STZ, fasting insulin concentrations were lower relative to vehicle (pâ<â0.05 for all) but remained modestly higher than CD-fed rats. Unfortunately, due to poor blood circulation in the tails of animals that received 150âmg/kg and 200âmg/kg STZ, we could not collect enough blood to determine insulin concentrations in these animals, but based on the characteristics of these animals it is highly likely that both groups had very low circulating insulin.
Osmotic mini-pump-infused STZ dose-dependently decreased glucose tolerance
Glucose tolerance was assessed on day 0, day 20 and day 35 using a 1âg/kg i.p. injection of glucose (Fig. 4). The total exposure to glucose during the glucose tolerance test was quantified by calculating the area under the curve (AUC) for each test (Fig. 5A). On day 20 all HFD-fed rats exhibited significantly higher glucose concentrations across the first 30âmin (Fig. 4B; pâ<â0.05), culminating in a significant increase in total glucose AUC relative to day 0 across all groups (Fig. 5A; pâ<â0.01). On day 35, glucose tolerance was not different between HFD and vehicle treated rats (Figs 4B,C and 5A). Animals that received 80â100âmg/kg STZ exhibited significantly increased glucose concentrations from 30â90âmin (pâ<â0.05) but returned toward baseline over the final 30âmin of the glucose tolerance test (Fig. 4DâF). All three STZ groups exhibited a marked increase in AUC during the glucose tolerance test relative to vehicle treated rats (Fig. 5A). Treatment with 110âmg/kg STZ caused a further decline in glucose tolerance and glucose concentrations remained significantly elevated relative to baseline across the time-course of the glucose tolerance test (Fig. 4G; pâ<â0.01). Increasing STZ further to 120âmg/kg, 150âmg/kg and 200âmg/kg resulted in step-wise increases in glucose concentrations across the 120âmin test where there was minimal return baseline (Fig. 4HâJ). These findings were mirrored by step-wise increases in glucose AUC during the glucose tolerance test for each dose of STZ (Fig. 5A; pâ<â0.001 vs vehicle and preceding STZ dose for all). Plotting the STZ dose versus the resulting AUC (Fig. 5B) revealed a tight sigmoidal, dose-dependent relationship where STZ appears to have small effects on glucose tolerance at 80âmg/kg and near maximal effects at 150âmg/kg.
Osmotic mini-pump-infused STZ reduced insulin release during a glucose tolerance test
Plasma was collected at 0, 10, 20 and 60âmin during the day-35 glucose tolerance test (Fig. 6) in all groups with the exception of the 150 and 200âmg/kg STZ groups. In CD-fed animals, a significant rise in plasma insulin concentrations was detected 10âmin following glucose injection (41â±â4 vs. 155â±â32 pmol/l; pâ<â0.001) but quickly returned toward baseline at 20 (73â±â8 pmol/l; pâ=â0.482) and 60âmin (48â±â5 pmol/l; pâ=â0.786). Both the HFD-only and HFD+ vehicle treated groups had higher plasma insulin concentrations at 10âmin (287â±â42 and 249â±â32 pmol/l), 20âmin (257â±â76 and 286â±â49 pmol/l) and 60âmin (110â±â25 and 156â±â12 pmol/l) compared with CD (pâ<â0.05 for all time-points). Animals that received 80âmg/kg STZ had modest increases in insulin concentrations at 10âmin (125â±â14 pmol/l; pâ=â0.291), 20âmin (116â±â10 pmol/l; pâ=â0.151) and 60âmin (121â±â25 pmol/l; pâ=â0.244) relative to their baseline. Similarly, at 90âmg/kg STZ, circulating insulin increased modestly following glucose injection at 10âmin (102â±â25 pmol/l; pâ=â0.265), 20âmin (133â±â22 pmol/l; pâ=â0.127) and 60âmin (111â±â20 pmol/l; pâ=â0.319) relative to bassline. At 100âmg/kg STZ, insulin concentrations were higher at 10âmin (102â±â23 pmol/l; pâ=â0.387), but returned toward baseline at 20âmin (75â±â19 pmol/l; pâ=â0.522) and 60âmin (79â±â16 pmol/l; pâ=â0.709). Relative to vehicle treated animals, the rats that received 80, 90 and 100âmg/kg STZ exhibited reduced insulin concentrations at 10 and 20âmin following glucose administration (Fig. 6; pâ<â0.001 for all). Animals that received 110âmg/kg and 120âmg/kg STZ did not exhibit increased insulin levels at any time-points following glucose administration and had lower insulin concentrations relative to vehicle treated animals at all time-points (Fig. 6; pâ<â0.05 for all).
Pancreatic tissue was collected from each animal and representative sections are shown for each group (Supplementary Figure 2). Islets from CD, HFD and vehicle (panels AâC) treated animals had similar structure and stained heavily for insulin/pro-insulin. At STZ doses of 80â120âmg/kg, there appeared to be a step-wise decline in islet staining for insulin/pro-insulin, while islet structure shifted from oval toward irregular in shape (panels DâH). Very few islets were present in sections from 150âmg/kg and 200âmg/kg STZ groups (panels I and J) and when located, exhibited almost no staining for insulin/pro-insulin.
Discussion
In the present study, we demonstrate a novel method that allows for targeted and sustained induction type 2 diabetes in rats by combining a HFD with osmotic mini-pump-infused STZ. In our model, HFD feeding led to obesity, increased circulating NEFA and insulin concentrations and glucose intolerance, typical of insulin resistance/pre-diabetes in both rodents7,22 and humans23. The addition of STZ after three weeks of HFD feeding caused a dose-dependent increase in circulating glucose and further decline in glucose tolerance while preserving an obese, dyslipidemic phenotype. Critically, the dose-dependent decline in glucose tolerance was accompanied by a reciprocal, dose-dependent decrease in insulin secretion in response to the glucose load. Thus, for the first time our novel approach enables targeted induction of type 2 diabetes across the spectrum of disease. This approach is a significant advance for modelling distinct stages of type 2 diabetes (i.e. during the phase of declining beta cell function) that ultimately provides a powerful platform for modelling type 2 diabetes and associated pathologies.
Once in the circulation, STZ is transported into pancreatic beta cells by the glucose transporter 2 (GLUT2) protein24,25. Within the beta cell, STZ interrupts a number of important cellular processes and if the insult is sufficient, culminates in DNA damage and cell death24,25. The end result of STZ administration is the reduction of functional beta cell mass that manifests as insulin deficiency and subsequent inability to handle glucose25. Coupling this insulin insufficiency with the challenge of a HFD, where increased insulin is required to account for cellular insulin resistance26,27, induces a state of glucose intolerance8, typical of human type 2 diabetes. In the present study, we demonstrate that the combination of HFDâ+âSTZ infused by osmotic mini-pump enables excellent phenotypic control with targeted induction of hyperglycemia and glucose intolerance, while maintaining a state of obesity. Furthermore, we confirmed that the dose-dependent effect of STZ we observed is due to a reciprocal reduction in insulin secretory capacity and morphological changes to the pancreas. To our knowledge, no other method currently allows such precise control over the resulting level of hyperglycaemia and glucose intolerance. Therefore, we believe this is the first animal model capable of reproducing different stages of type 2 diabetes defined by dose-dependent effects of STZ on glucose intolerance, reduced beta cell function and ensuing hyperglycemia while retaining an obese dyslipidemic profile.
All current methods for delivering STZ employ injections (e.g. IP or IV). Whilst these are exclusively utilised in the literature (due to the prevailing notion that STZ degrades quickly in solution), injection methods also impose significant limitations to the resulting phenotype. IP injections yield highly variable results due to the exact injection site and thus influences the absorbance rate of STZ into the systemic circulation. This may account for some of the inconsistencies in the literature where similar doses of STZ (e.g. 35âmg/kg) are reported to have very different effects on glucose tolerance8,28,29. Similar issues confound studies using IV injection to administer STZ, where at the same dose as IP (35âmg/kg), IV injections are reported to be just as variable in their effectiveness30,31. Generally, the IV method appears to be preferred, likely due to a more targeted and direct mode of delivery15. However, relative to IP, IV injections are more technically challenging without providing significant improvement over the resulting level of hyperglycemia. A recent study in guinea pigs demonstrated that subcutaneous injection of STZ (200âmg/kg) could improve overall efficacy but only when animals are also treated with the α-adrenergic receptor antagonist yohimbine12. In the present study, we show consistent, reproducible and dose-dependent effects by utilising subcutaneously implanted osmotic mini-pumps to infuse STZ over the course of 14 days.
Injection methods cause spikes in circulating STZ concentrations and as such, STZ has a very short time-frame to affect pancreatic beta cells. Whether this short, single-pass insult to the beta cells is sufficient to induce cell death is highly dependent on the dose of STZ utilised. Indeed, animals injected with lower STZ doses (15â30âmg/kg IP or IV) have been reported to revert back to normoglycemia, and thus require repeat low-dose injections to maintain the hyperglycaemic phenotype18. Conversely, animals injected with higher STZ doses (â¥50âmg/kg IP or IV) exhibit overt hyperglycemia, complete absence of insulin, weight loss and as such are prone to a high mortality rate15,18,32. In support of one previous study33 and in contrast the prevailing belief that STZ degrades quickly, we report that STZ undergoes an isomer switch and remains relatively stable for at least 14 days. This opens the door to novel avenues of STZ administration, such as the osmotic mini-pump, where STZ can be released slowly and consistently into the circulation over 14 days. Therefore, rather than a large spike in STZ, cells are exposed to low circulating concentrations of STZ resulting in a sustained 14-day insult. Importantly, even though circulating STZ concentration is relatively low compared to injection methods, the sensitivity of beta cells to STZ-induced damage is evident from the rapid and sustained effects on glucose handling, circulating insulin and pancreatic histology. Thus, we conclude that the overall improvement in effectiveness observed in our study is likely due to sustained, chronic exposure of STZ to beta cells. Our data suggest that a sustained low-grade insult to beta cells produces more consistent and precise effects than that of a large dose with single-pass uptake. Therefore, administering STZ using osmotic mini-pumps imparts significantly greater control over the resulting level of hyperglycemia while retaining an obesogenic phenotype.
From an animal welfare perspective and in accordance with the NC3Rs and the ARRIVE guidelines for animal research34, our effective STZ dose range of 80â120âmg/kg led to consistent metabolic effects in all animals (zero non-responders) and resulted in zero inadvertent animal deaths. While these statistics are generally poorly reported in the literature as a whole, our method is a marked improvement on previous publications where animals either do not respond to STZ injection (~10â15%) or die as a result of STZ injection (â¥30%)15,33. Taken together, these data demonstrate that our new method required fewer animals to observe significant effects compared with previous reports15,33. As noted above, the improvement in efficacy that we observed is likely due to the prevailing concentration of STZ in the circulation following injection (very high) or osmotic mini-pump infusion (very low) and the resulting effects on not just the highly sensitive beta cells, but also all other cells in the body.
It should be noted that while our method is a significant advance in the field, the HFDâ+âSTZ model itself remains somewhat artificial with regard to human type 2 diabetes pathogenesis. Indeed, individuals with type 2 diabetes progress through a far longer stage of insulin resistance-associated hyperinsulinemia, which ultimately leads to beta cell dysfunction5,6. While our model involves a background of HFD-induced insulin resistance7,22, the administration of STZ does not replicate the exact cause of beta cell death as seen in humans. While this imposes some limitations on this model, the use of STZ greatly accelerates the time-frame for development of hyperglycemia and glucose intolerance that may not otherwise occur in rodents with relatively short life-spans. Importantly, the result of both human type 2 diabetes and STZ administration is the same, development of sustained hyperglycemia, which ultimately drives the pathological features of type 2 diabetes such as microvascular disease, neuropathies and nephropathy.
In conclusion, our new approach provides a significant advance and enables induction of distinct stages of clinical type 2 diabetes in rodents. Ultimately, this new model provides a powerful platform for identification of preventative and therapeutic strategies targeting the spectrum of type 2 diabetes and associated pathologies.
Materials and Methods
Stability of STZ across 14âdays
The stability of STZ over the 14 day delivery period of the osmotic mini-pump was determined using reverse-phase high performance liquid chromatography (HPLC) as previously described33. Briefly, four independent STZ solutions (3.5âmg/ml) were prepared in citrate buffered saline (pH 4.4) and kept in the dark at 37â°C for 14 days. STZ (40âµl) was injected into a C18 column (5âµm, Gemini, Phenomenex, CA, USA) and analysed under isocratic conditions using a flow rate of 1.0âml/min with a 3% methanol/97% acetate buffer (pH 4.4) and detection at a wavelength of 250ânm. To investigate the α and β STZ anomer equilibration dynamics, each solution was sampled at 0, 20, 40, 60, 80 and 100âmin after dissolution. To investigate STZ degradation across 14 days, each solution was subsequently sampled every two days after dissolution.
Animal husbandry
All experimental procedures were approved by the University of Tasmania Animal Ethics Committee and performed in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes â 2013, 8th Edition. Male Sprague Dawley rats aged 14â16 weeks were obtained from the University of Tasmania animal facility or Monash Animal Services and allowed to acclimatise for 7 days upon arrival. Rats were randomised and housed in groups of three at 21â±â2â°C with a 12âhr-12âhr light-dark cycle. All animals were provided with water and chow ad libitum for throughout the study. With the exception of control diet (CD) only fed rats, all other groups were provided with a high fat diet (HFD; 23% fat by weight; simple carbohydrate replacement; Specialty Feeds, WA, Australia) ad libitum throughout the study (see Fig. 2A).
Osmotic mini-pump implantation and STZ dosage
Following three weeks of HFD, STZ (Sigma Aldrich, St Louis, MO, USA) was infused at a constant rate (5âµL/hr) over a 14-day period using a subcutaneously implanted osmotic mini-pump (Alzet Model 2ML2; Durect Corporation, Cupertino, CA, USA). Briefly, rat anesthesia was maintained using isoflurane throughout the surgical procedure. Following sterile preparation of the surgical site, a 1.5âcm incision (perpendicular to the spine) was made through the skin on the dorsum of the animals at the lumbar level of the spinal cord. Blunt dissection was used to separate connective tissue between the skin and underlying muscle layers to allow for insertion of the osmotic mini-pump. Loaded mini-pumps were inserted and positioned inside the cavity between the scapulae so that delivery of solution occurred away from the surgical site. The incision site was sealed using dissolvable sutures and animals allowed to recover.
There are no previous reports of STZ delivery using osmotic mini-pumps. Due to the slow flow rate of the osmotic mini-pumps, we tested seven different STZ concentrations to establish an STZ dose-response curve. STZ was prepared in citrate buffered saline (0.1âmmol/l; pH 4.4) and a total volume of 2âml was loaded into mini-pumps 20â30âmin prior to surgical implant. The seven STZ doses we tested were; i) 200âmg/kg; ii) 150âmg/kg; iii) 120âmg/kg; iv) 110âmg/kg; v) 100âmg/kg; vi) 90âmg/kg; and vii) 80âmg/kg (these doses represent the total amount of STZ delivered to the animal over 14 days). Given the flow rate of the 2ML2 pump (5âµl/hr) and assuming all animals weighed 500âg on the day of implant, this would equate to STZ doses of; i) 0.25âmg/hr; ii) 0.19âmg/hr; iii) 0.15âmg/hr; iv) 0.14âmg/hr; v) 0.13âmg/hr; vi) 0.11âmg/hr; and vii) 0.10âmg/hr over a 14-day period. These equated to a dose-range of 2.4â6âmg/day, far lower than the 20â100âmg/kg doses used typically in IP or IV experiments8,28,29,30,31. Vehicle treated rats received mini-pumps containing citrate buffered saline (pH 4.4; 2âml). To control for any diet-specific effects, two additional groups of rats were maintained on CD or HFD only for the duration of the 35-day protocol (Fig. 1). Thus, a total of 10 groups were used in the present study.
Assessment of metabolic alterations
Food intake, water intake, body weight and non-fasting blood glucose concentrations were assessed every 3â4 days for the duration of the 35-day intervention (see Fig. 2A). Non-fasting glucose concentrations were determined using a hand-held glucometer (Accu-Chek Performa, Roche Diagnostics, NSW, Australia) by making a small incision to the tip of the tail to access blood. To assess changes in glucose handling over the 35-day intervention each animal underwent a glucose tolerance test at three distinct time-points; i) Day 0 - baseline; ii) Day 20 â HFD-induced insulin resistance; and iii) Day 35 â following STZ or vehicle delivery.
All glucose tolerance tests were performed on overnight fasted rats. Briefly, animals received an intraperitoneal injection of glucose (1âg/kg). Blood was accessed from the tip of the tail and glucose concentrations were measured at 0, 10, 20, 30, 45, 60, 75, 90, 105 and 120âmin following glucose injection. During the day 35 glucose tolerance test, larger volumes of blood (2â3 drops) were collected at 0, 10, 20 and 60âmin following glucose injection in pre-heparinised tubes, centrifuged and plasma stored at â20â°C. Plasma insulin (Mercodia Rat Insulin ELISA, Uppsala, Sweden) and non-esterified fatty acid concentrations (NEFA-C; Wako Pure Chemical Industries, Osaka, Japan) were determined according to the manufacturerâs instructions.
Data and statistics
All data generated or analysed during this study are included in this published article (and its Supplementary Information files). Statistics and graphical presentation of data was carried out using Sigma Plot 11 (Systat Software, San Jose, CAL, USA). In instances where data was not normally distributed, Kruskal-Wallis one way ANOVA on Ranks was utilised with Student-Newman-Keulâs post-hoc. Where data was normally distributed, one-way ANOVA with Student-Newman-Keulâs post-hoc was group differences at a single time-point and two-way repeated measures ANOVA with Student-Newman-Keulâs post-hoc was utilised for all time-course comparisons. A value of pâ<â0.05 was considered statistically significant.
References
International Diabetes Federation. Diabetes Atlas, 7th edition. Brussels, Belgium (2015).
Guariguata, L. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice 103, 137â149 (2014).
Chen, L., Magliano, D. J. & Zimmet, P. Z. The worldwide epidemiology of type 2 diabetes mellitusâpresent and future perspectives. Nature Reviews Endocrinology 8, 228â236 (2012).
Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813â820 (2001).
Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840â846 (2006).
Reaven, G. M. Role of insulin resistance in human disease. Diabetes 37, 1595â1607 (1988).
Premilovac, D. et al. Muscle insulin resistance resulting from impaired microvascular insulin sensitivity in Sprague Dawley rats. Cardiovascular research 98, 28â36 (2013).
Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C. & Ramarao, P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacological research 52, 313â320 (2005).
Srinivasan, K. & Ramarao, P. Animal models in type 2 diabetes research: an overview. Indian Journal of Medical Research 125, 451 (2007).
Reed, M. et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49, 1390â1394 (2000).
Anderson, N. J., King, M. R., Delbruck, L. & Jolivalt, C. G. Role of insulin signaling impairment, adiponectin and dyslipidemia in peripheral and central neuropathy in mice. Disease models & mechanisms 7, 625â633 (2014).
Podell, B. K. et al. A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment. Disease Models & Mechanisms, dmm. 025593 (2017).
Oakes, N. D., Cooney, G. J., Camilleri, S., Chisholm, D. J. & Kraegen, E. W. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 46, 1768â1774 (1997).
Hong, Y. H. et al. No effect of NOS inhibition on skeletal muscle glucose uptake during in situ hindlimb contraction in healthy and diabetic Sprague-Dawley rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 308, R862âR871 (2015).
SkovsÞ, S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. Journal of diabetes investigation 5, 349â358 (2014).
Stranahan, A. M. et al. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nature neuroscience 11, 309â317 (2008).
Kleinridders, A., Ferris, H. A., Cai, W. & Kahn, C. R. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63, 2232â2243 (2014).
Zhang, M., Lv, X.-Y., Li, J., Xu, Z.-G. & Chen, L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Experimental Diabetes Research 2008 (2009).
Mansor, L. S. et al. Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin. Cardiovascular diabetology 12, 1 (2013).
Bonner-Weir, S. et al. β-cell growth and regeneration: replication is only part of the story. Diabetes 59, 2340â2348 (2010).
Finegood, D. T., Scaglia, L. & Bonner-Weir, S. Dynamics of β-cell mass in the growing rat pancreas: estimation with a simple mathematical model. Diabetes 44, 249â256 (1995).
Premilovac, D. et al. Blueberry tea enhances insulin sensitivity by augmenting insulin-mediated metabolic and microvascular responses in skeletal muscle of high fat fed rats. International Journal of Diabetology & Vascular Disease Research 1, 1â10 (2013).
Keske, M. A., Clerk, L. H., Price, W. J., Jahn, L. A. & Barrett, E. J. Obesity blunts microvascular recruitment in human forearm muscle after a mixed meal. Diabetes Care 32, 1672â1677, https://doi.org/10.2337/dc09-0206 (2009).
Elsner, M., Tiedge, M., Guldbakke, B., Munday, R. & Lenzen, S. Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan. Diabetologia 45, 1542â1549 (2002).
Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51, 216â226, https://doi.org/10.1007/s00125-007-0886-7 (2008).
Olefsky, J., Crapo, P. A., Ginsberg, H. & Reaven, G. M. Metabolic effects of increased caloric intake in man. 495â503 (1975).
Reaven, G. M. & Olefsky, J. M. Role of insulin resistance in the pathogenesis of hyperglycemia. Advances in Modern Nutrition 2, 229â265 (1978).
Hu, S.-H., Jiang, T., Yang, S.-S. & Yang, Y. Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes 121, 220â224 (2013).
Khan, H. B. H., Vinayagam, K. S., Moorthy, B. T., Palanivelu, S. & Panchanatham, S. Anti-inflammatory and anti-hyperlipidemic effect of Semecarpus anacardium in a High fat diet: STZ-induced Type 2 diabetic rat model. Inflammopharmacology 21, 37â46 (2013).
Hussein, A.-A. M., Abdel-Aziz, A., Gabr, M. & Hemmaid, K. Z. Myocardial and metabolic dysfunction in type 2 diabetic rats: impact of ghrelin. Canadian journal of physiology and pharmacology 90, 99â111 (2011).
Danda, R. S. et al. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney international 68, 2562â2571 (2005).
Si, Y. et al. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats identification of a novel role in improving insulin sensitivity. Diabetes 61, 1616â1625 (2012).
de la Garza-Rodea, A. S., KnaÀn-Shanzer, S., den Hartigh, J. D., Verhaegen, A. P. & van Bekkum, D. W. Anomer-equilibrated streptozotocin solution for the induction of experimental diabetes in mice (Mus musculus). Journal of the American Association for Laboratory Animal Science 49, 40â44 (2010).
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS biology 8, e1000412 (2010).
Acknowledgements
This work was funded by the National Health and Medical Research Council of Australia (grant code APP1088952).
Author information
Authors and Affiliations
Contributions
D.P., R.G., M.K., B.T., A.W. and L.F. were involved in experimental conception and design. D.P. contributed to all data collection unless otherwise noted. S.S. contributed to pancreatic sectioning and staining. All authors contributed to the writing and editing of the manuscript. D.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Premilovac, D., Gasperini, R.J., Sawyer, S. et al. A New Method for Targeted and Sustained Induction of Type 2 Diabetes in Rodents. Sci Rep 7, 14158 (2017). https://doi.org/10.1038/s41598-017-14114-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-017-14114-4
This article is cited by
-
Combined analysis of whole-exome sequencing and RNA sequencing in type 2 diabetes mellitus patients with thirst and fatigue
Diabetology & Metabolic Syndrome (2022)
-
Clinically relevant experimental rodent models of diabetic foot ulcer
Molecular and Cellular Biochemistry (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.